Commentary
Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer
Abstract
EML4-ALK is a fusion-type protein-tyrosine kinase generated through a recurrent chromosome rearrangement, a small inversion within the short arm of chromosome 2, inv(2)(p21p23) (1).
